Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

NCT01428063 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: Daclatasvir
DRUG: Asunaprevir
DRUG: Pegylated interferon alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb